Clinically Amyopathic Dermatomyositis Associated with Recurrence of Esophageal Cancer: A Case Report
Main Article Content
Keywords
clinically amyopathic dermatomyositis, CADM, esophageal adenocarcinoma
Abstract
Background: Approximately 20% of patients displaying skin changes characteristic of dermatomyositis do not develop clinical or enzymatic evidence of muscle inflammation within 6 months of onset, leading to a diagnosis of clinically amyopathic dermatomyositis (CADM). While the association between dermatomyositis and malignancy is well-documented, the clinical significance of CADM is still being elucidated.
Case Presentation: We report a case of new-onset CADM associated with recurrent esophageal adenocarcinoma for clinical interest and to add to the limited literature on CADM.
Conclusion: To date, there is only one report of concurrent CADM and esophageal cancer. We present this case for clinical interest and to add to the limited literature on CADM.
References
2) Sato S, Kuwana M. Clinically amyopathic dermatomyositis. Curr Opin Rheumatol 2010;22:639-43.
3) Lu X, Yang H, Shu X, et al. Factors predicting malignancy in patients with polymyositis and dermatomyostis: a systematic review and meta-analysis. PLoS ONE. 2014;9(4):e94128.
4) Goyal S, Nousari HC. Paraneoplastic amyopathic dermatomyositis associated with breast cancer recurrence. J Am Acad Dermatol.1999;(41):874-875.
5) Kikuchi K, Seto Y, Matsubara T, et al. Amyopathic dermatomyositis associated with esophageal cancer. Int J Dermatol. 2008;47:310-311.
6) Gerami P, Schope JM, Mcdonald L, Walling HW, Sontheimer RD. A systematic review of adult-onset clinically amyopathic dermatomyositis (dermatomyositis siné myositis): a missing link within the spectrum of the idiopathic inflammatory myopathies. J Am Acad Dermatol. 2006;54(4):597-613.
7) Galimberti F, Li Y, Fernandez AP. Clinically amyopathic dermatomyositis: clinical features, response to medications and malignancy-associated risk factors in a specific tertiary-care-centre cohort. Br J Dermatol. 2016;174(1):158-64.
8) Yu, B. A clinical analysis of cutaneous type dermatomyositis. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 1994;16:394-396.
9) Joseph CG, Darrah E, Shah AA, et al. Association of the autoimmune disease scleroderma with an immunologic response to cancer. Science. 2014;343:152-7.
10) Leatham H, Schadt C, Chisolm S, et al. Evidence supports blind screening for internal malignancy in dermatomyositis: Data from 2 large US dermatology cohorts. Medicine (Baltimore). 2018;97(2):e9639.
11) Sontheimer RD. Clinically amyopathic dermatomyositis: what can we now tell our patients? Arch Dermatol. 2010;146(1):76-80.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.
Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.
Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.